Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1225 of 2529 entries
View as:

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Phase: N/A Priority: Normal
NCT ID: NCT01235962 Org: User:
Start: 11/30/10 End: 04/15/19 Due: 04/15/20

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01290380 Org: User:
Start: 02/28/10 End: - Due: -

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03176264 Org: User:
Start: 09/25/17 End: 01/30/18 Due: 01/30/19

An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)

Phase: N/A Priority: Normal
NCT ID: NCT01736540 Org: User:
Start: 02/28/13 End: 05/31/15 Due: 05/31/16

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Phase: N/A Priority: Normal
NCT ID: NCT02159040 Org: User:
Start: 09/11/14 End: 06/26/15 Due: 06/26/16

Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day

Phase: N/A Priority: Normal
NCT ID: NCT00700271 Org: User:
Start: 10/31/07 End: 08/31/08 Due: 08/31/09

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03048448 Org: User:
Start: 05/31/17 End: 04/22/19 Due: 04/22/20

Dose Escalation of HSP990 in Japan/Korea

Phase: N/A Priority: Normal
NCT ID: NCT01064089 Org: User:
Start: 02/28/10 End: 01/31/12 Due: 01/31/13

A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

Phase: N/A Priority: Normal
NCT ID: NCT01103050 Org: User:
Start: 03/22/10 End: 07/28/10 Due: 07/28/11

Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

Phase: N/A Priority: Normal
NCT ID: NCT00501852 Org: User:
Start: 07/31/07 End: - Due: -

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Phase: N/A Priority: Normal
NCT ID: NCT04285723 Org: User:
Start: 06/09/20 End: 04/16/21 Due: 04/16/22

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT00379483 Org: User:
Start: 07/31/02 End: 04/30/03 Due: 04/30/04

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Phase: N/A Priority: Normal
NCT ID: NCT01619332 Org: User:
Start: 03/31/12 End: 09/30/13 Due: 09/30/14

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT01336634 Org: User:
Start: 08/05/11 End: 01/07/21 Due: 01/07/22

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT02190604 Org: User:
Start: 07/31/12 End: 11/30/15 Due: 11/30/16

Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.

Phase: N/A Priority: Normal
NCT ID: NCT06042478 Org: User:
Start: 11/15/23 End: 07/20/27 Due: 07/20/28

Effect of Indacaterol on Inspiratory Capacity (IC)

Phase: N/A Priority: Normal
NCT ID: NCT01012765 Org: User:
Start: 11/30/09 End: - Due: -

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Phase: N/A Priority: Normal
NCT ID: NCT01860066 Org: User:
Start: 12/31/13 End: 09/30/14 Due: 09/30/15

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05349214 Org: User:
Start: 08/04/22 End: 05/12/27 Due: 05/12/28

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Phase: N/A Priority: Normal
NCT ID: NCT00740129 Org: User:
Start: 10/21/08 End: 03/14/11 Due: 03/14/12

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT07006727 Org: User:
Start: 07/15/25 End: 03/14/31 Due: 03/14/32

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Phase: N/A Priority: Normal
NCT ID: NCT04788615 Org: User:
Start: 07/23/21 End: 02/13/26 Due: 02/13/27

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

Phase: N/A Priority: Normal
NCT ID: NCT05462990 Org: User:
Start: 11/09/22 End: 04/08/25 Due: 04/08/26

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Phase: N/A Priority: Normal
NCT ID: NCT06293365 Org: User:
Start: 07/02/24 End: 02/13/29 Due: 02/13/30

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Phase: N/A Priority: Normal
NCT ID: NCT05976243 Org: User:
Start: 12/07/23 End: 12/31/28 Due: 12/31/29